Sylvester Comprehensive Cancer Center
Doral, FL
Accepting patients
MagnetisMM-30
A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma
- Bispecific T Cell Engager (BiTE)
- Bispecific Antibody
- BCMA
- CD3
- Phase 1
- Has results